Effect of anti-glycosphingolipid monoclonal antibodies in pathogenic fungal growth and differentiation. Characterization of monoclonal antibody MEST-3 directed to Manp α1→3Manp α1→2IPC
© Toledo et al; licensee BioMed Central Ltd. 2010
Received: 15 June 2009
Accepted: 15 February 2010
Published: 15 February 2010
Studies carried out during the 1990's demonstrated the presence of fungal glycoinositol phosphorylceramides (GIPCs) with unique structures, some of them showed reactivity with sera of patients with histoplasmosis, paracoccidioidomycosis or aspergillosis. It was also observed that fungal GIPCs were able to inhibit T lymphocyte proliferation "in vitro", and studies regarding the importance of these molecules to fungal survival showed that many species of fungi are vulnerable to inhibitors of sphingolipid biosynthesis.
In this paper, we describe a detailed characterization of an IgG2a monoclonal antibody (mAb), termed MEST-3, directed to the Paracoccidioides brasiliensis glycolipid antigen Pb-2 (Manp α1→3Manp α1→2IPC). mAb MEST-3 also recognizes GIPCs bearing the same structure in other fungi. Studies performed on fungal cultures clearly showed the strong inhibitory activity of MEST-3 on differentiation and colony formation of Paracoccidioides brasiliensis, Histoplasma capsulatum and Sporothrix schenckii. Similar inhibitory results were observed when these fungi where incubated with a different mAb, which recognizes GIPCs bearing terminal residues of β-D-galactofuranose linked to mannose (mAb MEST-1). On the other hand, mAb MEST-2 specifically directed to fungal glucosylceramide (GlcCer) was able to promote only a weak inhibition on fungal differentiation and colony formation.
These results strongly suggest that mAbs directed to specific glycosphingolipids are able to interfere on fungal growth and differentiation. Thus, studies on surface distribution of GIPCs in yeast and mycelium forms of fungi may yield valuable information regarding the relevance of glycosphingolipids in processes of fungal growth, morphological transition and infectivity.
Drouhet  described the existence of over 72,000 species of fungi widespread in nature, and more than 300 may be associated with human mycoses. In the last two decades, it was observed a dramatic raise in mortality of immunosupressed individuals associated with fungal infection. Although antifungal therapies have been successful and selective, the outbreaks of resistant strains, together with an increase on fungal tolerance levels to currently available antifungal, were described by several reports [1, 2]. Therefore, a compelling search for novel antifungal therapies has been greatly stimulated. Studies carried out during the 1990s demonstrated that many species of fungi are vulnerable to inhibitors of enzymes of the sphingolipid biosynthesis pathway, such as inositol phosphorylceramide (IPC) synthase [3, 4]. This particular enzyme transfers myo-inositol-1-phosphate from phosphatidylinositol to ceramide, the first and an essential step for the biosynthesis of glycoinositol phosphorylceramides (GIPCs), a class of complex anionic glycosphingolipids (GSLs) widely distributed among fungal species [5–7]. In this manner, GIPCs synthesis are highly susceptible to IPC synthase inhibitors, which in turn are remarkably toxic to many mycopathogens, but exhibit low toxicity in man, since the IPC or IPC-synthase gene are absent in mammals .
The detailed characterization of GIPCs from a variety of fungi revealed an extensive structural diversity. Based on further studies, more than 30 distinct GIPC structures have been identified to date, which may present one of the 3 well-confirmed core structures distinguishable at the monoglycosyl level and absent in mammals [5–7]. Some of these GIPCs have antigenic glycoside determinants, such as terminal β-D-galactofuranose residues, which are recognized by human sera, suggesting their potential as targets for immunodiagnostic and the possibility of therapy based on stimulation of mammalian humoral response [8–15]. It should be emphasized that the expression of these GIPCs is considerably dependent on species, and at least for some mycopathogens, strongly regulated during morphogenesis [8–11, 13, 16–23].
Reactivity of mAbs MEST-1, -2 and -3, with different fungi preparation
Manp α1→3Manp α1→2Ins
Characterization of mAb MEST-3
Indirect immunofluorescence with MEST-3
Effect of monoclonal antibodies on fungal growth
Effect of monoclonal antibodies on fungal dimorphism
mAb MEST-3 specificity
In this paper, we describe the characterization of MEST-3, an IgG2a monoclonal antibody directed to the structure (Manp α1→3Manp α1→2IPC) from GIPC Pb-2 of P. brasiliensis. Among different methyl-glycosides, disaccharides and glycosylinositols, only Manp α1→3Manp and Manp α1→3Manp α1→2Ins inhibited MEST-3 binding to Pb-2 in solid-phase RIA. Furthermore, MEST-3 was unable to recognize, by solid-phase RIA or HPTLC-immunostaining, the intact GIPC Ss-M2 (Manp α1→3Manp α1→6IPC), thus suggesting that α1→6 linkage of the subterminal mannose unit to inositol represents a sterical hindrance for antigen recognition by MEST-3. Therefore, the minimum epitope required for optimum binding of MEST-3 to Pb-2 and similar GIPCs, would comprise the two linear mannose residues in specific linkage and the myo-inositol residue as follows: Manp α1→3Manp α1→2Ins.
By indirect immunofluorescence, it was observed that MEST-3 is reactive only with yeast forms of P. brasiliensis, H. capsulatum and S. schenckii, which is in agreement with previous data describing the crypticity of GIPC Pb-3 and GlcCer in mycelium forms of P. brasiliensis [13, 24]. Accordingly, despite the detection of the GIPC Pb-2 extracted from hyphae of P. brasiliensis by HPTLC and HPTLC immunostaining with mAb MEST-3, it should be noted the complete lack of MEST-3 reactivity by immunofluorescence with fixed mycelia forms. Taking together, these data suggest that a particular organization of GSLs and/or cell wall structure, distinct from that found in yeast forms, is required for mAb MEST-3 binding to fungal GIPC Pb-2. In this context, the access of antibodies directed to GSLs of mycelium forms seems to be strongly affected by organizational or structural aspects that do not favor the interaction antigen-antibody.
Growth and dimorphism inhibition by anti-glycosphingolipid mAbs
There are several reports in the literature showing the importance of neutral glycosphingolipids, such as cerebrosides, on fungal growth and morphological transition [25–27]. Rodrigues et al.  described that the addition of purified human antibodies, directed to GlcCer from Cryptococcus neoformans, inhibited cell budding and growth of this fungus. Therefore, the effects of three mAbs (MEST-1, -2 and -3), directed to different fungal GSLs, were analyzed on colony formation (CFU) of pathogenic dimorphic fungi (P. brasiliensis, H. capsulatum and S. schenckii). Experiments using mAb MEST-2, directed to fungal GlcCer, showed no significant inhibition of CFU or effect in dimorphism of the fungi studied. These data do not corroborate the results from Rodrigues et al. . Possible explanations for these results may be related to the source of the antibodies, human and murine, in our case, or fungal species, since this effect was only observed in C. neoformans.
Our results using mAb MEST-1, directed to Pb-3 and Hc-Y3, showed significant inhibition of fungal growth and differentiation of P. brasiliensis and H. capsulatum from yeast to mycelia. As expected, no inhibition with MEST-1 was observed for S. schenckii, since this specie does not express galactofuranose-bearing GSLs. On the other hand, MEST-3 was able to inhibit CFU, fungal growth and differentiation of all three fungi studied. MEST-3 was able to cause higher inhibition of CFU and differentiation for H. capsulatum and S. schenckii than for P. brasiliensis. This lower degree of inhibition showed by P. brasiliensis could be attributed to the low GIPC Pb-2 concentration in yeast forms of this fungus . On the other hand, GIPCs Hc-Y2 and Ss-Y2, which bear the same structure as Pb-2, represent about 30% and 20% of acidic glycolipid fraction from H. capsulatum and S. schenckii yeast forms respectively [8, 23].
Conversely, results observed in the mycelium to yeast transformation, were not straightforward, a possible explanation could be related to the non-reactivity of mAbs MEST-1, -2 and -3, with mycelia forms, as observed by immunofluorescence assay (Table 1). Moreover, in H. capsulatum and S. schenckii, the transformation of mycelium to yeast takes at least three weeks in normal conditions, and the mycelium web hinders clear yeast observation and quantification.
It is now well established that the precise build up of lipid rafts is necessary to efficiently guide signal transduction through cell membrane , some new evidences indicate that in fungi, these constructions are also necessary for fungal survival and maintenance of the infection . Two attractive hypotheses for the inhibitory activity of mAbs MEST-1 and MEST-3 on the yeast growth and differentiation would be: i) the association mAb-GIPCs sterically inhibits the formation of functional glycosphingolipid-enriched microdomains (GEM), thus blocking the action of key enzymes responsible for cell wall synthesis , and ii) an already existing microdomain to which a mAb-GIPC association takes place is not functional, hindering essential signal transduction to fungal growth and/or dimorphism. Confocal microscopy, with P. brasiliensis cell wall stained with calcofluor white indicates two places of MEST-3 binding, i) extensive and internal to calcofluor labeling, i.e. plasma membrane, and ii) discrete external as well as co-labeling with calcofluor, these preliminary data led us to suggest a new conceptual model of GSL arrangements in yeast forms where microdomain-like regions containing GIPCs could also be located at the external surface of the cell wall. Further work to substantiate this concept model is under investigation in our laboratory aiming an extensive comprehension of fungal glycosphingolipid enriched microdomains regarding their composition, surface localization, role in signaling processes and possible role in host cell binding and infection.
This study and others have shown that specific GIPCs are found in a large variety of pathogenic fungi [6, 7]. In some cases, those GIPCs are recognized by sera from patients with paracoccidioidomycosis, histoplasmosis or aspergillosis [8–10, 13–15, 32], indicating that GIPCs are immunogenic and able to induce the production of human antibodies during fungal infections. The broad distribution of GIPCs in pathogenic fungi and the antifungal activity of monoclonal antibodies directed to GIPCs indicate that these molecules may represent potential targets for the development of new therapeutical approaches based on induction of protective antibodies.
The fine specificity of MEST-3 was assessed by inhibition assays using different methyl-glycosides, disaccharides and oligosaccharides. Only Manα1→3Man and the glycoinositol Manα1→3Manα1→2Ins, from Pb-2, were able to inhibit, by about 95%, MEST-3 binding to Pb-2 antigen of P. brasiliensis. The epitope recognized by MEST-3 was defined as Manα1→3Manα1→2Ins; this structure was already described in a variety of pathogenic fungi [5–11, 15–17, 19, 23]. Studies using mAbs MEST-3 and MEST-1, as fungal growth inhibitors showed that anti-GIPCs mAbs presented a strong inhibitory activity on growth, differentiation and colony formation of P. brasiliensis, H. capsulatum, and S. schenckii. On the other hand, no statistically significant inhibition was observed with anti-GlcCer (MEST-2).
These results strongly suggest that mAbs directed to particular glycosphingolipids are able to interfere on fungal growth and differentiation. An attractive hypothesis is that, by hindering the formation of functional lipid rafts by association with mAbs, a possible dependence of surface organization of glycosphingolipids in fungi is essential for different fungal processes, such as growth, morphological transition, and infectivity.
Fungal isolates and growth conditions
Paracoccidioides brasiliensis strain Pb18 was provided by Dr Z.P. Camargo, São Paulo, SP, Brazil. Yeast and mycelia forms of P. brasiliensis were grown at 37°C and 25°C, respectively, in PGY (peptone 5 g/L, glucose 15 g/L, yeast extract 5 g/L) using 2.5 L Fernbach flasks in a shaker at 100 rpm . Histoplasma capsulatum strain 496 from human pulmonary lesion  and Sporothrix schenckii strain 65 from human foot cutaneous lesion [22, 23], were kindly provided by Dr O. Gompertz, São Paulo, SP, Brazil. Yeast and mycelia forms of both fungi were grown in Brain Heart Infusion (BHI) (37 g/L) at 37°C and 25°C, respectively. After 5-7 days both yeast and mycelia forms of the various fungi were inactivated with 0.1% of thimerosal, and after an additional 48 h the fungi were collected by filtration on Whatman n° 1 filter paper, except for yeast forms of S. schenckii and H. capsulatum, which were harvested by centrifugation at 5,200 × g for 20 minutes.
Extraction and purification of glycosphingolipids (GSLs)
GSLs were extracted by homogenizing yeast or mycelia forms (~ 30 g) in an Omni-mixer (Sorvall Inc. Wilmington, DE), three times with 200 ml of isopropanol/hexane/water (IHW, 55:20:25, v/v/v, upper phase discarded), and twice with 200 ml of chloroform/methanol (CM, 2:1, v/v). The five extracts were pooled, dried on rotary evaporator, dialyzed against water and lyophilized. Neutral and acidic GSLs were separated in a DEAE-Sephadex A-25 column as described by Yu and Ledeen . Fractions containing GIPCs, were assessed by HPTLC on silica gel 60 plates (E. Merck, Darmstadt, Germany) using solvent A: chloroform/methanol/CaCl2 0.02%, (60:40:9; v/v/v), and stained with orcinol/H2SO4. For preparative-scale HPTLC separated GSL bands were visualized under UV light after spraying with primulin 0.01% in 80% aqueous acetone . GSLs were isolated from silica gel scraped from the plates by repeated sonication in IHW, as described .
Production of hybridomas
About 600 μg of GIPC Pb-2 purified from mycelia forms of P. brasiliensis were dissolved in 1.5 ml of distilled water and mixed with 1.5 mg of acid-treated heat-inactivated Salmonella minnesota. Aliquots (100 μl) of this suspension containing 40 μg of the antigen were used to immunize six weeks old BALB/c mice, by i.v. route, through the caudal vein once a week, over 4 weeks. After a rest period of 30 days, the immune response was boosted with 200 μl of the immunogenic complex. Three days later, the mice were sacrificed and their spleen removed. The lymphocytes were fused with NS-1 myeloma cells and placed in 96-well plates. Solid-phase RIA detected hybrids secreting immunoglobulins reacting with Pb-2. Only clones showing strong reactivity with Pb-2 of mycelia and yeast forms of P. brasiliensis were cloned by limited dilution as described [13, 24, 37]. Research ethical approval (CEP 0023/06) was granted by the Ethical Research Committee Boards of Universidade Federal de São Paulo.
Various GSLs were adsorbed on 96-well plates (Falcon Microtest III flexible assay plates, Oxnard, CA). Solutions (25 μl/well, 100 ng/first well) in ethanol of different GSLs were serially diluted, dried at 37°C and wells blocked with 1% bovine serum albumin (BSA) in 0.01 M phosphate-buffered saline (PBS), pH 7.2 (200 μl) for 2 h, and sequentially incubated with mAb MEST-3 (100 μl) overnight at 4°C, rabbit anti-mouse IgG (50 μl) for 2 h, and with 50 μl of 125I-labeled protein A in PBS with 1% of BSA (about 105 cpm/well) for 1 h. The amount of mAb MEST-3 bound to Pb-2 was determined by measuring the radioactivity in each well in a gamma counter .
Release of glycosylinositols by ammonolysis
Ammonolysis of GIPCs was performed as described by Barr and Lester  and Levery et al. . Briefly, 100 μg of GIPCs Pb-2 and Ss-Y2 were heated in a Teflon-lined screw-capped test tube with 10 N NH3.H20 (~ 1 mL) for 18 h at 150°C. The solution was cooled and evaporated under N2 stream at 37°C; this process was repeated after addition of a few drops of 2-propanol. The residue was sonicated in 1 mL of water and the lipophilic components were removed by passage of this solution through a small C18-silica solid-phase extraction cartridge, washing twice with 1 ml of water. The combined aqueous fraction containing free glycosylinositol was lyophilized and used for inhibition of antibody binding to GIPCs Pb-2.
Inhibition of antibody binding by different methyl glycosides, disaccharides and glycosylinositols
Initially, 75 μl of a 200 mM solution of several methyl-α- and β-D-glycosides (glucopyranoside, galactopyranoside and mannopyranoside), disaccharides (Manα1→2Man, Manα1→3Man and Manα1→6Man), purchased from Sigma (MO, USA), and the glycosylinositols (Manα1→3Manα1→2Ins and Manα1→3Manα1→6Ins, described above), were serially diluted with PBS in a 96-well plate. Each glycoside solution was incubated with 75 μl of MEST-3 at room temperature . After 2 h, aliquots of 100 μl were taken and incubated overnight at 4°C in 96-well plates pre-coated with the GIPC Pb-2 (100 ng/well) essentially as described under Binding assay.
Ninety-six-well plates were coated with different concentrations (100 ng to 5 pg) of GIPC Pb-2 and treated with 5 and 20 mM of sodium m-periodate in PBS (0.1 M, pH 7.0) at room temperature for 30 min . The plates were washed with PBS, reduced with NaBH4 (50 mM in PBS) during 30 min, blocked with 5% of BSA in PBS for 1 h, and incubated overnight with mAb MEST-3, and processed as described in Binding Assay.
High performance thin layer chromatography (HPTLC) immunostaining
GIPCs purified from different fungi were separated by HPTLC, and the immunostaining of the plates was performed by the procedure of Magnani et al. , modified by Zuolo et al.  and Takahashi et al. . GSLs (3 μg) were separated in solvent A: C:M:CaCl2 0.02% (60:40:9; v/v/v), after development, the plates were dried, soaked in 0.5% polymethacrylate in hexane, dried, and blocked for 2 h with 1% of BSA in PBS. Plates were then incubated with mAb MEST-3 overnight followed by sequential incubations with rabbit anti-mouse IgG and 125I-labeled protein A (2 × 107 cpm/50 ml of BSA/PBS).
Fungi were fixed with 1% formaldehyde in PBS for 10 min. Cells were washed, suspended in 1 ml of PBS, and 20 μl of the solution was added to a coverslip pre-treated with poly-L-lysine 0.1% during 1 h. Air dried preparations were soaked for 1 h in PBS containing 5% of BSA, and incubated subsequently with culture supernatant of mAb MEST-3 (2 h), biotin-conjugated goat anti-mouse IgG (1 h), and with avidin-conjugated fluorescein (1 h). After each incubation the coverslips were washed five times with PBS. The coverslips were examined with an epifluorescence microscope . Control experiments for each fungus were carried out, in the presence of an irrelevant monoclonal antibody, and no fluorescence was observed.
To evaluate the influence of mAbs directed to GSLs on the growth of different fungi, yeasts (104/ml) were incubated in 96-well plate in the presence of mAbs MEST-1, -2, or -3 for 24 h at 37°C, in concentration ranging from 2.5 to 50 μg/ml. The growth rate was evaluated by two procedures; 1) viable CFU were evaluated by plating 100 μl of the samples onto BHI or PGY agar plates, followed by incubation for 2 days at 37°C, and colony counting; or 2) 5 μl of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/ml MTT in phosphate-buffered saline, pH 7,4) were added to each well and the plates were further incubated at 37°C, for 3 h, after incubation the medium containing MTT was partially removed, and dimethyl sulfoxide (100 μl) was added to solubilize the MTT formazan product . The absorbance of each well was measured at 580 nm by a microtiter ELISA plate reader. Control systems were similarly treated with an irrelevant immunoglobulin (normal mouse total Ig) and plated. All experiments were repeated three times in triplicates, and the results shown are a representative of these experiments.
Fungal differentiation - yeast to mycelium
104 viable yeasts were suspended in 1 ml of PGY (P. brasiliensis) or BHI (H. capsulatum and S. schenckii) medium. The suspension was incubated in a 24-well plate and supplemented with mAb MEST-1, -2, or -3 (at a concentration of 2.5, 10, 25 or 50 μg/ml), after one hour at 37°C, 24-well plate was transferred to a 24°C incubator and kept for 2 days. The number of yeast showing hyphae growth was counted, and presented as percentage of those incubated with irrelevant immunoglobulins (normal mouse total Ig). In control experiment 100% of yeast showed hyphae formation. For each mAb concentration, 300 viable fungi (yeast or transforming-yeast) were counted, yeasts differentiating into mycelia forms were observed and evaluated considering hyphae formation. Control experiments were performed identically, with the addition of irrelevant immunoglobulins. Experiments were performed in triplicate sets and representative results are shown in Figure 5.
Fungal differentiation - mycelium to yeast
A 5 days old culture containing hyphae, was washed and combined in a tube with sterile PBS and 5 mm glass beads, this suspension was agitated in vortex (3 × 5 min), to broke the web mycelia in small hyphae. After decantation, the supernatant containing short lengths of hyphae was centrifuged and the hyphae suspended in 1 ml of PGY medium. The suspension was incubated in a 24-well plate and supplemented with mAb MEST-1, -2, or -3 (at a concentration of 2.5, 10, 25 or 50 μg/ml), at 37°C. After 48 h and 96 h of incubation cultures were analyzed under inverted microscopy. Controls experiments were performed identically, with the substitution of mAb to irrelevant immunoglobulins (normal mouse total Ig).
‡This work was supported by FAPESP, CNPq and CAPES.
- Drouhet E: Historical introduction. Medical Mycology. Edited by: Ajello L, Hay R. 1998, Arnold New York, 3-42.Google Scholar
- François IEJA, Aerts AM, Cammue BPA, Thevissen K: Currently Used Antimycotics: Spectrum, Mode of Action and Resistance Occurrence. Current Drug Targets. 2005, 6: 895-907. 10.2174/138945005774912744.View ArticlePubMedGoogle Scholar
- Takesako K, Kuroda H, Inoue T, Haruna F, Yoshikawa Y, Kato I, Uchida K, Hiratani T, Yamaguchi H: Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic. J Antibiot. 1993, 46: 1414-1420.View ArticlePubMedGoogle Scholar
- Georgopapadakou NH: Antifungals targeted to sphingolipid synthesis: focus on inositol phosphorylceramide synthase. Expert Opin Investig Drugs. 2000, 9: 1787-1796. 10.1517/135437126.96.36.1997.View ArticlePubMedGoogle Scholar
- Nagiec MM, Nagiec EE, Baltisberger JA, Wells GB, Lester RL, Dickson RC: Sphingolipid synthesis as a target for antifungal drugs. Complementation of the inositol phosphorylceramide synthase defect in a mutant strain of Saccharomyces cerevisiae by the AUR1 gene. J Biol Chem. 1997, 272: 9809-9817. 10.1074/jbc.272.15.9809.View ArticlePubMedGoogle Scholar
- Suzuki E, Tanaka AK, Toledo MS, Levery SB, Takahashi HK, Straus AH: Trypanosomatid and fungal glycolipids and sphingolipids as infectivity factors and potential targets for development of new therapeutic strategies. Biochim Biophys Acta. 2008, 1780: 362-369.View ArticlePubMedGoogle Scholar
- Takahashi HK, Toledo MS, Suzuki E, Tagliari L, Straus AH: Current relevance of fungal and trypanosomatid glycolipids and sphingolipids: studies defining structures conspicuously absent in mammals. An Acad Bras Cienc. 2009, 81: 477-488.View ArticlePubMedGoogle Scholar
- Barr K, Lester RL: Occurrence of novel antigenic phosphoinositol-containing sphingolipids in the pathogenic yeast Histoplasma capsulatum. Biochemistry. 1984, 23: 5581-5588. 10.1021/bi00318a031.View ArticlePubMedGoogle Scholar
- Barr K, Laine RA, Lester RL: Carbohydrate structures of three novel phosphoinositol-containing sphingolipids from the yeast Histoplasma capsulatum. Biochemistry. 1984, 23: 5589-5596. 10.1021/bi00318a032.View ArticlePubMedGoogle Scholar
- Toledo MS, Suzuki E, Straus AH, Takahashi HK: Glycolipids from Paracoccidioides brasiliensis. Isolation of a galactofuranose-containing glycolipid reactive with sera of patients with paracoccidioidomycosis. J Med Vet Mycol. 1995, 33: 247-251. 10.1080/02681219580000501.View ArticlePubMedGoogle Scholar
- Levery SB, Toledo MS, Straus AH, Takahashi HK: Structure elucidation of sphingolipids from the mycopathogen Paracoccidioides brasiliensis : An immunodominant β-galactofuranose residue is carried by a novel glycosylinositol phosphorylceramide antigen. Biochemistry. 1998, 37: 8764-8775. 10.1021/bi9730083.View ArticlePubMedGoogle Scholar
- Straus AH, Suzuki E, Toledo MS, Takizawa C, Takahashi HK: Immunochemical characterization of carbohydrate antigens from fungi, protozoa and mammals by monoclonal antibodies directed to glycan epitopes. Braz J Med Biol Res. 1995, 28: 919-923.PubMedGoogle Scholar
- Suzuki E, Toledo MS, Takahashi HK, Straus AH: A monoclonal antibody directed to terminal residue of beta-galactofuranose of a glycolipid antigen isolated from Paracoccidioides brasiliensis : cross-reactivity with Leishmania major and Trypanosoma cruzi. Glycobiology. 1997, 7: 463-468. 10.1093/glycob/7.4.463.View ArticlePubMedGoogle Scholar
- Bertini S, Colombo AL, Takahashi HK, Straus AH: Expression of antibodies directed to Paracoccidioides brasiliensis glycosphingolipids during the course of paracoccidioidomycosis treatment. Clin Vaccine Immunol. 2007, 14: 150-156. 10.1128/CVI.00285-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Toledo MS, Levery SB, Bennion B, Guimarães LL, Castle SA, Lindsey R, Momany M, Park C, Straus AH, Takahashi HK: Analysis of glycosylinositol phosphorylceramides expressed by the opportunistic mycopathogen Aspergillus fumigatus. J Lipid Res. 2007, 48: 1801-1824. 10.1194/jlr.M700149-JLR200.View ArticlePubMedGoogle Scholar
- Aoki K, Uchiyama R, Itonori S, Sugita S, Che FS, Isogai A, Hada N, Takeda T, Kumagai H, Yamamoto K: Structural elucidation of novel phosphocholine-containing glycosylinositol-phosphoceramide in filamentous fungi and their induction of cell death of cultured rice cells. Biochem J. 2004, 378: 461-472. 10.1042/BJ20031307.PubMed CentralView ArticlePubMedGoogle Scholar
- Bennion B, Park C, Fuller M, Lindsey R, Momany M, Jennemann R, Levery SB: Glycosphingolipids of the model fungus Aspergillus nidulans : characterization of GIPCs with oligo-alpha-mannose-type glycans. J Lipid Res. 2003, 44: 2073-2088. 10.1194/jlr.M300184-JLR200.View ArticlePubMedGoogle Scholar
- Heise N, Gutierrez ALS, Mattos KA, Jones C, Wait R, Previato JO, Mendonça-Previato L: Molecular analysis of a novel family of complex glycoinositolphosphoryl ceramides from Cryptococcus neoformans : Structural differences between encapsulated and acapsular yeast forms. Glycobiology. 2002, 12: 409-420. 10.1093/glycob/cwf053.View ArticlePubMedGoogle Scholar
- Simenel C, Coddeville B, Delepierre M, Latgé JP, Fontaine T: Glycosylinositolphosphoceramides in Aspergillus fumigatus. Glycobiology. 2008, 18: 84-96. 10.1093/glycob/cwm122.View ArticlePubMedGoogle Scholar
- Wells GB, Dickson RC, Lester RL: Isolation and composition of inositolphosphorylceramide-type sphingolipids of hyphal forms of Candida albicans. J Bacteriol. 1996, 178: 6223-6226.PubMed CentralPubMedGoogle Scholar
- Toledo MS, Levery SB, Straus AH, Suzuki E, Momany M, Glushka J, Moulton JM, Takahashi HK: Characterization of sphingolipids from mycopathogens: Factors correlating with expression of 2-hydroxy fatty acyl (E)-Δ3-unsaturation in cerebrosides of Paracoccidioides brasiliensis and Aspergillus fumigatus. Biochemistry. 1999, 38: 7294-7306. 10.1021/bi982898z.View ArticlePubMedGoogle Scholar
- Toledo MS, Levery SB, Glushka J, Straus AH, Takahashi HK: Structure elucidation of sphingolipids from the Sporothrix schenckii: Identification of novel glycosylinositol phosphorylceramides with core Manα1→6Ins linkage. Biochem Biophys Res Commun. 2001, 280: 19-24. 10.1006/bbrc.2000.4091.View ArticlePubMedGoogle Scholar
- Toledo MS, Levery SB, Straus AH, Takahashi HK: Sphingolipids of the mycophatogen Sporothrix schenckii : identification of a glycosylinositol phosphorylceramide with novel core GlcNH2α1→2Ins motif. FEBS Letters. 2001, 493: 50-56. 10.1016/S0014-5793(01)02275-X.View ArticlePubMedGoogle Scholar
- Toledo MS, Suzuki E, Levery SB, Straus AH, Takahashi HK: Characterization of monoclonal antibody MEST-2 specific to glucosylceramide of fungi and plants. Glycobiology. 2001, 11: 105-112. 10.1093/glycob/11.2.105.View ArticlePubMedGoogle Scholar
- Kawai G, Ikeda Y: Chemistry and functional moiety of a fruiting-inducing cerebroside in Schizophyllum commune. Biochim Biophys Acta. 1983, 754: 243-248.View ArticleGoogle Scholar
- Kawai G, Ikeda Y: Structure of biologically active and inactive cerebrosides prepared from Schizophyllum commune. J Lipid Res. 1985, 26: 338-343.PubMedGoogle Scholar
- Kawai G: Molecular species of cerebrosides in fruiting bodies of Lentinus edodes and their biological activity. Biochim Biophys Acta. 1989, 1001: 185-190.View ArticlePubMedGoogle Scholar
- Rodrigues ML, Travassos L, Miranda KR, Franzen AJ, Rozental S, Souza W, Alviano CS, Barreto-Bergter E: Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infec Immun. 2000, 68: 7049-7060. 10.1128/IAI.68.12.7049-7060.2000.View ArticleGoogle Scholar
- Bagnat M, Keränen S, Shevchenko A, Shevchenko A, Simons K: Lipid rafts function in biosynthetic delivery of proteins to the cell surface in yeast. Proc Natl Acad Sci USA. 2000, 97: 3254-3259. 10.1073/pnas.060034697.PubMed CentralView ArticlePubMedGoogle Scholar
- Siafakas AR, Wright LC, Sorrell TC, Djordjevic JT: Lipid rafts in Cryptococcus neoformans concentrate the virulence determinants phospholipase B1 and Cu/Zn superoxide dismutase. Eukaryot Cell. 2006, 5: 488-498. 10.1128/EC.5.3.488-498.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Terashima H, Yabuki N, Arisawa M, Hamada K, Kitada K: Up-regulation of genes encoding glycosylphosphatidylinositol (GPI)-attached proteins in response to cell wall damage caused by disruption of FKS1 in Saccharomyces cerevisiae. Mol Gen Genet. 2000, 264: 64-74. 10.1007/s004380000285.View ArticlePubMedGoogle Scholar
- Levery SB, Toledo MS, Suzuki E, Salyan ME, Hakomori S, Straus AH, Takahashi HK: Structural characterization of a new galactofuranose-containing glycolipid antigen of Paracoccidioides brasiliensis. Biochem Biophys Res Commun. 1996, 222: 639-645. 10.1006/bbrc.1996.0796.View ArticlePubMedGoogle Scholar
- Toledo MS, Levery SB, Suzuki E, Straus AH, Takahashi HK: Characterization of cerebrosides from the thermally dimorphic mycopathogen Histoplasma capsulatum : expression of 2-hydroxy fatty N-acyl (E)-Delta(3)-unsaturation correlates with the yeast-mycelium phase transition. Glycobiology. 2001, 11: 113-124. 10.1093/glycob/11.2.113.View ArticlePubMedGoogle Scholar
- Yu RK, Ledeen RW: Gangliosides of human, bovine, and rabbit plasma. J Lipid Res. 1972, 13: 680-686.PubMedGoogle Scholar
- Straus AH, Levery SB, Jasiulionis MG, Salyan ME, Steele SJ, Travassos LR, Hakomori S, Takahashi HK: Stage-specific glycosphingolipids from amastigote forms of Leishmania (L.) amazonensis. Immunogenicity and role in parasite binding and invasion of macrophages. J Biol Chem. 1993, 268: 13723-13730.PubMedGoogle Scholar
- Straus AH, Valero VB, Takizawa CM, Levery SB, Toledo MS, Suzuki E, Salyan ME, Hakomori S, Barbieri CL, Takahashi HK: Glycosphingolipid antigens from Leishmania (L.) amazonensis amastigotes. Binding of anti-glycosphingolipid monoclonal antibodies in vitro and in vivo. Braz J Med Biol Res. 1997, 30: 395-399. 10.1590/S0100-879X1997000300014.View ArticlePubMedGoogle Scholar
- Straus AH, Travassos LR, Takahashi HK: ST-1 a monoclonal antibody specific for intact heparin. Anal Biochem. 1992, 201: 1-8. 10.1016/0003-2697(92)90167-6.View ArticlePubMedGoogle Scholar
- Magnani JL, Smith DF, Ginsburg V: Detection of gangliosides that bind toxin: direct binding of 125I-labeled toxin to thin-layer chromatography. Anal Biochem. 1980, 109: 399-402. 10.1016/0003-2697(80)90667-3.View ArticlePubMedGoogle Scholar
- Zuolo ML, Toledo MS, Nogueira HE, Straus AH, Takahashi HK: Identification of GM3 as a marker of therapy-resistant periradicular lesions. J Endodon. 2001, 27: 107-109. 10.1097/00004770-200102000-00012.View ArticleGoogle Scholar
- Takahashi HK, Metoki R, Hakomori S: Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated alpha-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen. Cancer Res. 1988, 48: 4361-4367.PubMedGoogle Scholar
- Derengowski LS, De-Souza-Silva C, Braz SV, Mello-De-Sousa TM, Báo SN, Kyaw CM, Silva-Pereira I: Antimicrobial effect of farnesol, a Candida albicans quorum sensing molecule, on Paracoccidioides brasiliensis growth and morphogenesis. Ann Clin Microbiol Antimicrob. 2009, 8: 13-10.1186/1476-0711-8-13.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.